Log in to search using one of your social media accounts:

 

telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 12:00:00 AMLast Editorial Review: 8/9/2017 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 9, 2017 Category: Nutrition Source Type: news

Incivek (Telaprevir Film-Coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news

​Five things you need to know today, and why old folks should love Boston
Good morning, Boston! Here are the five most important things you need to know to help start your busy business day. Why Vertex fell short on its job-creation vows to the city In May 2011, just days after the FDA approval of the first-ever drug by Vertex Pharmaceuticals, company executives had a lot of reasons to be optimistic. The company’s hepatitis C treatment, Incivek, was more effective and easier to use than rival drugs, and 1,750 jobs at its new headquarters seemed eminently reachable. When… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 12, 2015 Category: Biotechnology Authors: Doug Banks Source Type: news

Telaprevir Linked to Temporary Drop in Kidney FunctionTelaprevir Linked to Temporary Drop in Kidney Function
Using the protease inhibitor telaprevir may cause a temporary drop in kidney function in patients co-infected with HIV and hepatitis C virus (HCV), according to a small study. Reuters Health Information (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - March 31, 2015 Category: Urology & Nephrology Tags: HIV/AIDS News Source Type: news

Can Current Investment in New Drugs Be Sustained?
When blockbuster drugs hit the market, they make big news and big profits. But for every blockbuster drug launched, there are an awful lot of disappointments.A good example is Vertex’s launch of the Hepatitis C drug Incivek. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 18, 2015 Category: Pharmaceuticals Source Type: news

Incivek / Telaprevir - Treatment for Chronic Hepatitis C
Incivek (telaprevir) is a protease inhibitor used for treating hepatitis C infections in liver patients. (Source: Drug Development Technology)
Source: Drug Development Technology - January 2, 2015 Category: Pharmaceuticals Source Type: news

Addition of telaprevir good value in genotype 1 hepatitis C
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2015 Category: Drugs & Pharmacology Source Type: news

Simeprevir Effective for Treating Chronic HCV Genotype 1 InfectionSimeprevir Effective for Treating Chronic HCV Genotype 1 Infection
Simeprevir plus peginterferon and ribavirin is noninferior to telaprevir plus peginterferon and ribavirin for treating previous null or partial responders with chronic hepatitis C virus (HCV) genotype 1 infection, according to Janssen's ATTAIN trial. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 16, 2014 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Simeprevir-based therapy offers cost-effective alternative in treatment of hepatitis C
(University of Pennsylvania School of Medicine) Researchers at Penn Medicine, in collaboration with an international team, have shown that a protease inhibitor, simeprevir, along with interferon and ribavirin is as effective in treating chronic Hepatitis C virus infection as telaprevir with interferon and ribavirin, the standard of care in developing countries. Further, simeprevir proved to be simpler for patients and had fewer adverse events. The complete study is online and is scheduled to publish in January 2015 in The Lancet Infectious Diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2014 Category: Global & Universal Source Type: news

Vertex to End Sales of Hepatitis C Drug Telaprevir (Incivek)Vertex to End Sales of Hepatitis C Drug Telaprevir (Incivek)
Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its hepatitis C drug telaprevir (Incivek), whose use has been largely supplanted by new-comer sofosbuvir (Sovaldi) from Gilead Sciences. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 14, 2014 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Vertex to end sales of hepatitis C drug Incivek
(Reuters) - Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 13, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 4:15:00 PMLast Editorial Review: 7/21/2014 4:15:06 PM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - July 21, 2014 Category: Gastroenterology Source Type: news

telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 4:15:00 PMLast Editorial Review: 7/21/2014 4:15:06 PM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 21, 2014 Category: Drugs & Pharmacology Source Type: news

New hepatitis C drug treatment 'shows promise'
Conclusion Although designed as an RCT, the study had an analysis of drug effectiveness that becomes more like a single cohort of people receiving an active treatment, with no comparison arm. People were assigned to the five-drug combination or matching placebos for 12 weeks. During this time, the side effects in both treatment groups were monitored and these could be compared, with itching and anaemia occurring more commonly in the active treatment group. However, the double-blind drug treatment period was completed at 12 weeks and response outcomes were then assessed 12 weeks later. Twelve weeks later, the active treatm...
Source: NHS News Feed - April 14, 2014 Category: Consumer Health News Tags: Medication Medical practice Source Type: news

New hepatitis C drug treatment 'shows promise'
Conclusion Although designed as an RCT, the study had an analysis of drug effectiveness that becomes more like a single cohort of people receiving an active treatment, with no comparison arm. People were assigned to the five-drug combination or matching placebos for 12 weeks. During this time, the side effects in both treatment groups were monitored and these could be compared, with itching and anaemia occurring more commonly in the active treatment group. However, the double-blind drug treatment period was completed at 12 weeks and response outcomes were then assessed 12 weeks later. Twelve weeks later, the active treatm...
Source: NHS News Feed - April 14, 2014 Category: Consumer Health News Tags: Medication Medical practice Source Type: news

FDA Updates Raltegravir (Isentress) Labeling
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir. “In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.” The revised label is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Raltegravir (Isentress) patient fact sheet (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news

Telaprevir Effective for Treating Advanced Hepatitis CTelaprevir Effective for Treating Advanced Hepatitis C
Telaprevir appears effective and relatively safe for treating advanced hepatitis caused by HCV genotype 1, according to an open-label study from Janssen Pharmaceutics. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Telaprevir-Based Triple Therapy for Chronic Hepatitis CTelaprevir-Based Triple Therapy for Chronic Hepatitis C
How safe and effective is antiviral-based triple therapy for HCV patients with advanced fibrosis? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Costs for Hepatitis C Treatment SkyrocketCosts for Hepatitis C Treatment Skyrocket
The expense of telaprevir-based triple therapy for hepatitis C and related adverse events far surpasses the amount anticipated from registration trials. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Incivek (Telaprevir Film-Coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 8, 2013 Category: Drugs & Pharmacology Source Type: news

INCIVO data to be presented
Janssen Infectious Diseases-Diagnostics BVBA (Janssen) will present new data for INCIVO® (telaprevir) in combination with peginterferon alfa and ribavirin (PR) at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC, highlighting that earlier treatment improves patient outcomes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 4, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Infectious Disease Latest News Source Type: news

Vertex to Lay off 15% Due to Plunging Hep C Drug Sales
Despite the initial success of Vertex Pharmaceuticals' hepatitis C treatment, Incivek, in 2011, competition from all-oral hepatitis C treatments has damaged sales. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 29, 2013 Category: Pharmaceuticals Source Type: news

Analysis of HCV Variants in Patients Treated With TelaprevirAnalysis of HCV Variants in Patients Treated With Telaprevir
Will patients with HCV respond better to telaprevir with the addition of peginterferon/ribavirin? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

European Commission approves new twice daily dosing of INCIVO®
Janssen Infectious Diseases-Diagnostics BVBA (Janssen) has announced that the European Commission (EC) has approved a new twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral (DAA) protease inhibitor, in combination with pegylated-interferon and ribavirin (PR) for naive and previous treatment experienced patients. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news

Updated AIDSinfo Drug Database Offers Health Professionals and Patients the Latest HIV-Related Drug Information
The latest additions to the AIDSinfo drug database provide health care providers and patients with even more information on HIV/AIDS-related drugs.   Recent improvements to the database include: Investigational HIV drug summaries for health professionals that include the most recent information on pharmacology, dosing, adverse events, and drug interactions. The drug summaries also feature drug compound details from ChemIDplus Advanced (United States National Library of Medicine) and the HIV Drugs in Development Database from the National Institute of Allergy and Infectious Diseases (NIAID). Updated HIV investigat...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - May 31, 2013 Category: Infectious Diseases Source Type: news

Incivo® receives positive opinion
Janssen Infectious Diseases-Diagnostics BVBA (Janssen), has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral (DAA) for the treatment of chronic genotype-1 hepatitis C virus (HCV), in combination with pegylated-interferon and ribavirin (PR). (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 29, 2013 Category: Drugs & Pharmacology Source Type: news

FDA Updates Atripla Labeling
“FDA recently approved updates to the Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablet label to include the following changes: Lists Stribild as one of the drugs that should not be coadministered with Atripla Adds drug interaction information for raltegravir, boceprevir and telaprevir Strengthens Warnings and Precautions: Rash section Updates the Use in Specific Populations: Nursing Mothers section Updates Tables 7 and 8 with didanosine drug interaction data based upon recent changes to the prescribing information for Sustiva, Truvada and Viread.” The updated labeling will be a...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 19, 2013 Category: Infectious Diseases Source Type: news

Rapamune (sirolimus) tablets and oral solution - Pfizer Limited - Revised SPC
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Section 4.5 Interaction with other medicinal products and other forms of interaction has been updated to include potential interactions with CYP3A4 inhibitors, which may decrease the metabolism of sirolimus and increase sirolimus blood levels. Such inhibitors include e.g. certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole), certain antibiotics (e.g.  troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g. ritonavir, indinavir, boceprevir, telaprevir),  nicardipine, brom...
Source: NeLM - SPC Changes - March 1, 2013 Category: Drugs & Pharmacology Source Type: news

Australian government to provide $220m subsidy for important medicines
The Australian government is to provide $220m to subsidise vital medicines such as boceprevir and telaprevir, both prescribed for chronic hepatitis C, in a bid to help save more lives. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included. "Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding "Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news

Hepatitis C drug linked to 'fatal skin reaction'
If you or someone you know suffers from hepatitis C, you may want to think twice about succumbing to conventional drug treatment options, which could end up resulting in unexpected death. As reported by Army Times and others, Incivek (telaprevir), a popular drug used... (Source: NaturalNews.com)
Source: NaturalNews.com - January 17, 2013 Category: Consumer Health News Source Type: news

FDA warns telaprevir can cause fatal rash
Patients taking telaprevir for hepatitis C are at risk of developing a serious skin rash that could be fatal, the Food and Drug Administration has warned. (Source: Modern Medicine)
Source: Modern Medicine - January 4, 2013 Category: Journals (General) Source Type: news